CLINICAL_TRIALS ClinicalTrials.gov record update

Phase 1 Study of 9-ING-41, a Glycogen Synthase Kinase 3 Beta (GSK 3β) Inhibitor, as a Single Agent or With Irinotecan, Irinotecan Plus Temozolomide, or With Cyclophosphamide Plus Topotecan in Pediatric Patients With Refractory Malignancies.

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT04239092
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:27:34.762387+00:00
Published At: 2025-07-17T00:00:00+00:00
Record Updated At: 2025-07-17
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Refractory Cancer", "Refractory Neoplasm", "Cancer Pediatric", "Refractory Tumor", "Pediatric Cancer", "Pediatric Brain Tumor", "Neuroblastoma", "Neuroblastoma Recurrent", "Pediatric Lymphoma", "Pediatric Meningioma", "Diffuse Intrinsic Pontine Glioma"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2025-07-17"
protocolSection.identificationModule.nctId: "NCT04239092"
protocolSection.identificationModule.officialTitle: "Phase 1 Study of 9-ING-41, a Glycogen Synthase Kinase 3 Beta (GSK 3\u03b2) Inhibitor, as a Single Agent or With Irinotecan, Irinotecan Plus Temozolomide, or With Cyclophosphamide Plus Topotecan in Pediatric Patients With Refractory Malignancies."
protocolSection.statusModule.overallStatus: "TERMINATED"
protocolSection.designModule.phases: ["PHASE1"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.